がんの科学と治療

Hipec in Ovarian Cancer. Why is it Still the Ugly Duckling of Intraperitoneal Therapy?

Abstract

Pedro Antonio Cascales Campos, Jose Gil, Pablo Munoz-Ramon and Pascual Parrilla

What kind of intraperitoneal therapy would be recommend for our mother, sister, wife or daughter if she was diagnosed with advanced ovarian cancer and if we were in the office of an experienced surgeon able to achieve an optimal resection or, even better, a complete resection of her disease? If one was a surgeon who believed in postoperative systemic chemotherapy, one’s argument would be based on the results of the study GOG 172 (which coincided with a clinical alert from the NCI of the United States in favor of this modality of intraperitoneal treatment after optimal surgery in patients with ovarian cancer)